The Claim
In adults with type 2 diabetes and chronic kidney disease, weekly administration of 1.0 mg semaglutide reduces the risk of death from any cause by 20% compared to placebo, with a hazard ratio of 0.80 (95% CI, 0.67 to 0.95; P=0.01).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes and chronic kidney disease, taking 1.0 mg of semaglutide once a week results in a 20% lower risk of death from any cause compared to taking a placebo.
See the scientific wording
In adults with type 2 diabetes and chronic kidney disease, weekly administration of 1.0 mg semaglutide reduces the risk of death from any cause by 20% compared to placebo, with a hazard ratio of 0.80 (95% CI, 0.67 to 0.95; P=0.01), indicating a significant survival benefit in this high-risk population.
Semaglutide activates receptors in the kidneys and heart that reduce inflammation, lower blood pressure, and decrease the amount of protein leaking into the urine, which protects organs and prevents fatal complications.
What the research says
1 studyStudy: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
This study found that people with type 2 diabetes and kidney disease who took a weekly semaglutide shot were 20% less likely to die from any cause than those who took a placebo, meaning the drug helped them live longer.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.